Southborough, MA and Greenwich, CT (PRWEB) February 18, 2016
Corrona, a leader in real world evidence and related services in the auto-immune field, announced that on February 10, 2016 Raymond H. Hill was appointed Chief Executive Officer and Chairman of Corrona’s Board of Directors. Corrona is a portfolio company of the health care investment firm, Great Point Partners, based in Greenwich, CT. Mr. Hill has served for the past 15 months as Executive Chairman of Corrona.
Mr. Hill comes to Corrona with a solid track record of growing businesses in the health care space. Prior to joining Corrona, as President at InVentiv Health Clinical, a leading contract research organization (CRO), Mr. Hill was instrumental in driving EBITDA growth, securing key strategic partnerships, reducing employee attrition, and re-positioning the company. Mr. Hill previously served as President of IMS Consulting and Services (IMS Health) where he spearheaded work in portfolio strategy, pricing and market access, launch excellence, managed markets, and sales force effectiveness. Mr. Hill led IMS Health’s focus on commercial outsourcing, building a key vehicle for the business’ growth. Mr. Hill also served as the CEO of Pharmaceutical Product Development Inc., prior to taking the company private.
"I am thrilled that Ray has accepted the position of CEO and Chairman of the Board of Corrona. He has proven to be a great leader of the business over the last year of his tenure with the company, and has positioned Corrona on a solid growth trajectory for the future,” said Noah Rhodes, Managing Director at Great Point Partners. “His experience managing both clinically-oriented and data-oriented firms in the health care space has been a valuable addition to the business.”
“I have found the business at Corrona to be uniquely positioned in the real world evidence space. We have distinct assets that are difficult to replicate, which strengthens our business strategy,” said Mr. Hill. “We are doing innovative work now across six different registries in the USA and Japan, with real world patient and clinical data for autoimmune diseases. We are successfully expanding from our base in rheumatoid arthritis into therapeutic areas such as psoriasis. Across all of our registries, Corrona is well positioned to help companies understand how their drugs are used and how to optimize outcomes in the real world.”
Mr. Hill also serves as Chairman of the Board of Directors of Medivo LLC (http://www.medivo.com), based in New York City, and is a member of the Board of Directors of RowNewYork (http://www.rownewyork.org), a nonprofit in New York City. He is a graduate of Cornell University and received a Masters degree at Duke University.
Corrona was founded in 2000 by leading physicians dedicated to advancing and improving the care of patients with chronic diseases. Our mission is to advance research and improve the quality of patient care through world-class observational cohorts. Corrona provides data and research results to biopharmaceutical companies with an interest in our therapeutic areas of coverage. Our data is used to assist in trial design, comparative effectiveness, and to satisfy post market safety reporting. We are proud to be advised by experienced academic and clinical physicians throughout the country with a wide range of experiences. http://www.corrona.org
About Great Point Partners
Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP Fund II, which closed on $215 million in commitments in 2013. GPP manages capital in private equity and public equity funds, and has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies since inception. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, and specialty pharmaceuticals. The firm pursues a proactive and proprietary approach to sourcing investments. Contact Great Point Partners at 203-971-3300 or http://www.gppfunds.com.